Imagion Biosystems Limited (ASX:IBX)

Market Cap	9.81M +170.7%
Revenue (ttm)	73.03K -97.3%
Net Income	-4.31M
EPS	-0.02
Shares Out	490.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,914,668
Average Volume	2,236,079
Open	0.0200
Previous Close	0.0200
Day's Range	0.0200 - 0.0220
52-Week Range	0.0110 - 0.0550
Beta	-0.15
RSI	38.11
Earnings Date	Feb 26, 2026

About Imagion Biosystems

Imagion Biosystems Limited operates as a medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases in Australia. The company is involved in nanotechnology; biotechnology; medical imaging using magnetic resonance; and cancer diagnostics businesses. It develops MagSense, which is in Phase 2 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to magnetic relaxometry....

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2016
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IBX

Financial Performance

In 2025, Imagion Biosystems's revenue was 73,031, a decrease of -97.26% compared to the previous year's 2.67 million. Losses were -4.31 million, 108.5% more than in 2024.